In another sign Siemens is pivoting away from healthcare and towards the energy industry, the German conglomerate announced the sale of its hearing aid business for $2.69 billion to private equity firm EQT Partners and Santo Holding, the investment company of Germany's Strüngmann family.
Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry Valeant. And the business news outlets quickly identified Actavis as the interested party.
Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market.
Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will.
Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal 's sources, it's not all that mysterious.
Looking to build an oncology powerhouse, AstraZeneca has scooped up the diagnostics player Definiens with a down payment of $150 million while executing another drug development partnership with J&J and Pharmacyclics to add to its growing portfolio of immuno-oncology deals
Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.
Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.
Shares of IDEXX Laboratories rose nearly 5% to $141.67 last week after reporting third-quarter net income that handily beat analyst estimates and announcing the acquisition of Netherlands-based Animana, which makes software for veterinary practices.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.